Clinical activity of vofatamab (V), an FGFR3 selective antibody in combination with pembrolizumab (P) in metastatic urothelial carcinoma (mUC), updated interim analysis of FIERCE-22
Publication/Presentation Date
10-2019
Volume
30
Issue
5
First Page
365
Last Page
365
Published In/Presented At
Disciplines
Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods
Department(s)
Administration and Leadership
Document Type
Article
COinS